FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	dress of Reporting	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2020 3. Issuer Name and Ticker or Trading Symbol Orchard Therapeutics plc [ORTX]								
(Last) C/O ORCHA			Relationship of Reporting Perso (Check all applicable) Director		on(s) to Issue 10% Owne	(N	5. If Amendment, Date of Original Filed (Month/Day/Year)			
108 CANNO			X	Officer (give title below)	Other (spec	, 10.	Individual or Joint	/Group Filing (Check		
(Street) LONDON X0 EC4N 6EU					See Remark	S			y One Reporting Person y More than One erson	
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)				4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Ordinary Shares ⁽¹⁾						15,120	15,120 D			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security			4. Conversion or Exercis	e Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Stock Option ((Right to Buy)		(2)	02/06/2028	3	Ordinary Shares ⁽¹⁾	446,185	2.44	D	
Stock Option ((Right to Buy)		(3)	09/12/2028	3	Ordinary Shares ⁽¹⁾	184,229	9.06	D	
Stock Option (Right to Buy)		(4)	01/15/2029	9	Ordinary Shares ⁽¹⁾	100,000	12.54	D	

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. 124,407 shares subject to this option vested on January 15, 2019 and the remaining shares vest in equal monthly installments over the three years thereafter.
- 3. The shares subject to this option vest in equal monthly installments over the four years after September 13, 2018.
- 4. The shares subject to this option vest in equal monthly installments over the four years after January 16, 2019.

Remarks:

Exhibit 24 - Power of Attorney Title: Chief Financial Officer and Chief Operating Officer

<u>/s/ Frank Thomas</u> <u>01/02/2020</u>

** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned hereby constitutes and appoints each of John Ilett and Mark Rothera,

signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity
- as officer and/or director of Orchard Therapeutics plc (the "Company"), from time to time $\ensuremath{\mathsf{time}}$
- the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ${\tt ID}$, including
- any attached documents (such as Update Passphrase Authentication), to effect the assignment
- of codes to the undersigned to be used in the transmission of information to the SEC using
- the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities,
- including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership
- of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial
- Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of
- 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedule
- 13D and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of
- 1934, as amended, and the rules thereunder, including any attached documents;
- (2) do and perform any and all acts for and on behalf of the undersigned which
- may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D
- exchange, national association or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing
- which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of,
- such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall
- in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power

and authority to do and perform any and every act and thing whatsoever requisite, necessary or

proper to be done in the exercise of any of the rights and powers herein granted, as fully to all

intents and purposes as the undersigned might or could do if personally present, with full power

such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue

of this power of attorney and the rights and powers herein granted. The undersigned acknowledges

that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned,

are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply

with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The $\,$

undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against

any demand, damage, loss, cost or expense arising from any false or misleading information provided

by the undersigned to the attorneys-in-fact.

This Power of Attorney shall be governed by, and construed in accordance with, the laws of

the state of Delaware. This Power of Attorney shall remain in full force and effect until the

undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in

a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes

any prior power of attorney in connection with the undersigned's capacity as an officer and/or

director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact

if such attorney-in-fact ceases to be an officer of, or legal counsel to, the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 2, 2020.

> /s/ Frank Thomas Frank Thomas